Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy

Peritoneal Dialysis International

Volumn 18, Issue 3, 1998, Pages 282-289

  Van Guldener, Coen ^a,c   Janssen, Martien J F M ^b   Lambert, Jan ^a   Ter Wee, Piet M ^a   Donker, Ab J M ^a   Stehouwer, Coen D A ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b RIJNLAND HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Betaine; Endothelial function; Folic acid; Hyperhomocysteinemia; Treatment

Indexed keywords

BETAINE; BIOCHEMICAL MARKER; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; LONG TERM CARE; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

BETAINE; ENDOTHELIUM, VASCULAR; FEMALE; FOLIC ACID; HEMATINICS; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; TIME FACTORS;

EID: 0031880416     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Excerpts from the USRDS 1996 annual data report. Am J Kidney Dis 1996; 28:S79-102.
2. Raine AEG, Margreiter R, Brunner FP, Enrich JHH, Geerlings W, Landais P, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7:7-35.
3. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8:475-86.
4. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274:1049-57.
5. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775-81.
6. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. Arterioscler Thromb Vase Biol 1997; 17:2554-8.
7. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97:138-41.
8. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma homocysteine concentration. Scand J Clin Lab Invest 1996; 56:41-6.
9. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43(Suppl 41):S72-7.
10. Janssen MJFM, van Guldener C, de Jong GMT, van den Berg M, Stehouwer CDA, Donker AJM. Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 1996; 22:110-14.
11. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94:2743-8.
12. Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. At herosclerosis 1996; 122:163-72.
13. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98:24-9.
14. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95:1119-21.
15. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-9.
16. van Guldener C, Lambert J, Janssen MJFM, Donker AJM, Stehouwer CDA. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 1997; 12(Suppl 2):14-18.
17. Gris JC, Branger B, Vécina F, Al Sabadani B, Fourcade J, Schved JF. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994; 46:807-13.
18. Takagi M, Wada H, Mukai K, Kihira H, Yano S, Minamikawa K, et al. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coagul Fibrinolysis 1994; 5:713-17.
19. Arnadottir M, Brattström L, Simonsen O, Thysell H, Hultberg B, Andersson A, et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40:236-40.
20. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49:147-52.
21. Wilcken DEL, Gupta VJ, Betts AK. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci 1981; 61:743-9.
22. Bostom AG, Shemin D, Nadeau MR, Shih V, Stabler SP, Alien RH, et al. Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis 1995; 113:129-32.
23. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-81.
24. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346:1395-8.
25. Ubbink JB, Vermaak WJH, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565:441-6.
26. van den Berg M, Franken DG, Boers GHJ, Blom HJ, Jakobs C, Stehouwer CDA, et al. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocystememia. J Vasc Surg 1994; 20:933-40.
27. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111-15.
28. Lambert J, Aarsen M, Donker AJM, Stehouwer CDA. Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16:705-11.
29. Andersen TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26:1235-41.
30. Iwashima Y, Sato T, Watanabe K, Ooshima E, Hiraishi S, Ishii H, et al. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 1990; 39:983-8.
31. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340:319-23.
32. Thompson SG, Kienast J, Pyke SDM, Havercate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635-41.
33. Hamsten A, Walldius G, Szamosi A, Blombäck M, de Faire U, Dahlén G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii:3-9.
34. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89:1573-9.
35. Belch JJF, Shaw JW, Kirk G, McLaren M, Robb R, Maple C, et al. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation 1997; 95:2027-31.
36. Hoeks APG, Brands PJ, Smeets FAM, Reneman RS. Assessment of the distensibility of superficial arteries. Ultrasound Med Biol 1990; 16:121-8.
37. van Guldener C, Janssen MJFM, Lambert J, ter Wee PM, Jakobs C, Donker AJM, et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13:106-12.
38. Födinger M, Mannhalter C, Wölfl G, Pabinger I, Müller E, Schmid R, et al. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52:517-23.
39. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, et al. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996; 123:193-202.
40. van Guldener C, Janssen MJFM, Lambert J, Steyn M, Donker AJM, Stehouwer CDA. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant (in press).
41. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346:467-71.
42. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95:1126-31.